In unadjusted analysis, rates of DKA among individuals with an eGFR between 30 and 90 mL/min/1.73 m 2 showed no statistical difference compared with those with an eGFR between 90 and 120 mL/min/1.73 m ...

Even "normal" kidney test results may mask hidden risks if theyre unusually low for your age and sex, signaling higher chances of future disease.

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

Good afternoon, and welcome to Vir Biotechnology's conference call to discuss the company's VIR-5500 Strategic Collaboration with Astellas and Positive Phase I Data, and 2025 financial results. As a ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported EPS is $2.71, expectations were $2.65. Operator: Good morning, and thank you ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.